indications for glp 1 agonist The GLP-1 Agonists and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy Exciting developments in GLP-1 receptor

Description

For most users, that is the more useful default

& Wolfe, M

This is a truly exciting and transformational time for the treatment landscape for obesity. Survodutide (Boehringer Ingelheim and Zealand Pharma), an injectable glucagon/GLP-1 receptor agonist, was associated with up to 18.7% weight loss vs

Malhotra A, Grunstein RR, Fietze I et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity

If people stop medication, many are likely to need ongoing nutritional and behavioural support, and health services should anticipate that cardiometabolic benefits may lessen as weight is regained, Spreckley said, adding that this highlights the need for further research into effective, scalable strategies for long-term weight maintenance alongside pharmacotherapy. GLP-1 medications have become widely used in recent years, and more than 15 million Americans are now losing weight with the drugs